

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Harris *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: July 13, 2000

Examiner: To Be Assigned

For: Polypeptides Having Phospholipase B Activity And Nucleic Acids Encoding Same

**REQUEST TRANSFER OF COMPUTER READABLE
SEQUENCE LISTING FROM PARENT CASE**


Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The computer-readable form in this application, is identical with that filed in Application Serial No. **09/426,072** filed **October 21, 1999**, in accordance with 37 CFR 1.821 (e), please use the first filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally filed specification of the instant application.

The Examiner is hereby to contact the undersigned if there are any questions concerning this response.

Respectfully submitted,



Date: July 13, 2000

Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, New York 10017
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Harris *et al.*

Serial No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: July 13, 2000

Examiner: To Be Assigned

For: Polypeptides Having Phospholipase B Activity And Nucleic Acids Encoding Same

VERIFIED STATEMENT UNDER 37 CFR 1.821(f)

Assistant Commissioner for Patents
Washington, DC 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,

Date: July 13, 2000


Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
604 Lexington Avenue, Suite 6400
New York, New York 10017
(212) 867-0123